Compare Merck & Co., Inc. (MRK) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Merck & Co., Inc. trades at $132.76 (market cap $321.77B), while Direxion Daily Semiconductor Bear 3X Shares trades at $39.97. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| MRK | SOXS | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $131.84 | $1.49K |
52-Week Low | $77.60 | $32.50 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $39.97, down 11.59% in the past 24 hours amid a bearish technical signal. The ETF benefits from recent semiconductor sector weakness, with news highlighting its surge during chip stock sell-offs. A 1:10 stock split is scheduled for July 26, 2026, while technical indicators show oversold conditions with RSI at 26.30.
The outlook remains volatile, with SOXS positioned to gain from continued semiconductor sector pressure, though leveraged inverse exposure carries high risk. Key risks include rapid AI-driven chip rallies reversing bearish bets. Investors should weigh sector volatility against the ETF's structure, with support at $41 and resistance at $45.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
